Comparative Pharmacology
Head-to-head clinical analysis: EXKIVITY versus ROZLYTREK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXKIVITY versus ROZLYTREK.
EXKIVITY vs ROZLYTREK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversible tyrosine kinase inhibitor that selectively targets epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations, and specifically inhibits EGFR T790M and C797S resistance mutations, with less activity against wild-type EGFR.
Entrectinib is a potent inhibitor of tropomyosin receptor tyrosine kinases (TRK) A, B, and C, and also inhibits ROS1 and ALK. It blocks downstream signaling pathways including MAPK, PI3K/AKT, and PLCγ, leading to apoptosis and reduced tumor growth in cancers with NTRK or ROS1 fusions.
150 mg orally once daily with or without food.
200 mg orally once daily with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 48 hours, supporting once-daily dosing for systemic exposure.
Terminal half-life approximately 24 hours; supports once-daily dosing, steady-state reached in ~5 days.
Primarily hepatic metabolism with biliary excretion; 91% of total recovered in feces (30% as unchanged drug), <1% in urine.
Primarily hepatic metabolism via CYP3A4; 63% of dose recovered in feces (mostly as metabolites), 18% in urine (9% unchanged).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor